|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID 19 outpatients meta-analysis
|BLAZE-1 phase 2 (monotherapy)|
|RCT||bamlanivimab monotherapy||placebo||COVID 19 outpatients||some concern||101/156||inconclusive|
|1 study excluded by filtering options (0 RCT / 1 OBS)|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).